Drug-resistant tuberculosis medical therapy: Difference between revisions
| Line 38: | Line 38: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 1: First-line oral drugs</u>''' <br> | ||
▸ ''' Pyrazinamide''' <br> OR <br> ▸ '''Ethambutol ''' <br> OR <br> ▸ '''Rifabutin''' | ▸ ''' Pyrazinamide''' <br> OR <br> ▸ '''Ethambutol ''' <br> OR <br> ▸ '''Rifabutin''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 2: Injectable drugs</u>''' <br> | ||
▸ '''Kanamycin'''<br> OR <br> ▸ '''Amikacin'''<br> OR <br> ▸ '''Capreomycin'''<br> OR <br> ▸ '''Streptomycin''' | ▸ '''Kanamycin'''<br> OR <br> ▸ '''Amikacin'''<br> OR <br> ▸ '''Capreomycin'''<br> OR <br> ▸ '''Streptomycin''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 3: Fluoroquinolones</u>''' <br> | ||
▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ '''''' | ▸ '''Levofloxacin'''<br> OR <br> ▸ '''Moxifloxacin'''<br> OR <br> ▸ '''Ofloxacin''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4</u>''' <br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | '''<u>Group 4:Oral bacteriostatic second-line drugs</u>''' <br> | ||
▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> ▸ ''''''<br> OR <br> | ▸ '''Para-aminosalicylic acid'''<br> OR <br> ▸ '''Cycloserine'''<br> OR <br> ▸ '''Terizidone'''<br> OR <br> ▸ '''Ethionamide'''<br> OR <br> ▸ '''Protionamide''' | ||
|- | |- | ||
|} | |} | ||
Revision as of 15:18, 17 September 2014
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Drug-resistant tuberculosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Drug-resistant tuberculosis medical therapy |
|
Risk calculators and risk factors for Drug-resistant tuberculosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alejandro Lemor, M.D. [2]
Overview
Multiple Drug-Resistant (MDR) Tuberculosis
- MDR-TB is defined as resistance to isoniazid and rifampicin, with or without resistance to other first-line drugs.
- Medical treatment for MDR-TB consists of at least 4 drugs that have shown effectiveness against MDR.
|
MDR Tuberculosis ▸ Adults ▸ Children |
|
Extensively Drug-Resistant XDR Tuberculosis
XDR-TB is defined as resistance to at least isoniazid and rifampicin, and to any fluoroquinolone, and to any of the three second-line injectables (amikacin, capreomycin, and kanamycin).
|
XDR Tuberculosis ▸ Adults ▸ Children |
|